How to reduce antibiotic consumption for community-acquired pneumonia?

Medecine et Maladies Infectieuses

Volumn 43, Issue 2, 2013, Pages 52-59

  Montassier, E ^a,b   Goffinet, N ^a   Potel, G ^a,b   Batard, E ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Acute community acquired pneumonia; Clinical reassessment; Duration of antibiotic therapy; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; PROCALCITONIN;

ANTIBIOTIC THERAPY; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; DRUG USE; HUMAN; LENGTH OF STAY; REVIEW; SHORT COURSE THERAPY; STRATEGIC PLANNING; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; HOSPITALIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC; PROTEIN PRECURSORS; PULMONARY EDEMA;

EID: 84875814292     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2012.12.005     Document Type: Review

References (50)

1. Chidiac C. Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): the challenge of a new consensus conference. Med Mal Infect 2006, 36:535-537.
2. Elkharrat D., Chastang C., Baron D., Simon N. Management of patients with community-acquired pneumonia in French emergency departments. A prospective 3-month, multicenter study of 1424 patients. Interscience Conference on Antimicrobial Agents and Chemotherapy 1995, The French Study Group for CAP managed in the ED.
3. File T.M., Tan J.S., Plouffe J.F. Community-acquired pneumonia. What's needed for accurate diagnosis?. Postgrad Med 1996, 99:95-102. p105-107.
4. Bartlett J.G., Breiman R.F., Mandell L.A., Fine T.M. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998, 26:811-838.
5. Chandra A., Nicks B., Maniago E., Nouh A., Limkakeng A. A multicenter analysis of the ED diagnosis of pneumonia. Am J Emerg Med 2010, 28:862-865.
6. Syrjälä H., Broas M., Suramo I., Ojala A., Lähde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998, 27:358-363.
7. Hagaman J.T., Rouan G.W., Shipley R.T., Panos R.J. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. Am J Med Sci 2009, 337:236-240.
8. Castro-Guardiola A., Armengou-Arxé A., Viejo-Rodríguez A., Peñarroja-Matutano G., Garcia-Bragado F. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med 2000, 11:334-339.
9. Almirall J., Bolibar I., Toran P., Pera G., Boquet X., Balanzo X., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
10. Janssens J.P. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005, 11:226-230.
11. Roger P.M., Farhad R., Pulcini C., Mariette A., Taurel M., Oualid H., et al. Elderly patients presenting with fever and respiratory problems in an intensive care unit. Diagnostic, therapeutic and prognostic impact of a systematic infectious disease consultation. Presse Med 2003, 32:1699-1704.
12. Guillemot D., Maison P., Carbon C., Balkau B., Vauzelle-Kervroëdan F., Sermet C., et al. Trends in antimicrobial drug use in the community-France, 1981-1992. J Infect Dis 1998, 177:492-497.
13. Macfarlane J.T., Holmes W.F., Macfarlane R.M. Reducing reconsultations for acute lower respiratory tract illness with an information leaflet: a randomized controlled study of patients in primary care. Br J Gen Pract 1997, 47:719-722.
14. Agence française de sécurité sanitaire des produits de santé. Antibiothérapie par voie générale dans les infections respiratoires basses de l'adulte. Pneumonie aiguë communautaire. Exacerbations de bronchopneumopathie chronique obstructive, France, 2010.
15. Huchon G.J., Gialdroni-Grassi G., Léophonte P., Manresa F., Schaberg T., Woodhead M. Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 1996, 9:1590-1595.
16. Zahar J.R., Ghaffari P., Kamga I., Perronne V. Audit des prescriptions antibiotiques dans un service de maladies infectieuses. Presse Med 2003, 32(26):1208-1212.
17. Roger P.M., Martin C., Taurel M., Fournier J.P., Nicole I., Carles M., et al. Motives for the prescription of antibiotics in the emergency department of the University Hospital Center in Nice. A prospective study. Presse Med 2002, 31:58-63.
18. Li J.Z., Winston L.G., Moore D.H., Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007, 120(9):783-790.
19. Schuetz P., Christ-Crain M., Thomann R., Falconnier C., Wolbers M., Widmer I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
20. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
21. Goossens H., Ferech M., Vander Stichele R., Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005, 365:579-587.
22. Vernaz N., Huttner B., Muscionico D., Salomon J.L., Bonnabry P., López-Lozano J.M., et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011, 66:928-935.
23. Vellinga A., Murphy A.W., Hanahoe B., Bennett K., Cormican M. A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother 2010, 65:1514-1520.
24. Rogues A.M., Dumartin C., Amadéo B., Venier A.G., Marty N., Parneix P., et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007, 28:1389-1395.
25. Miliani K., L'Hériteau F., Lacavé L., Carbonne A., Astagneau P. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. J Hosp Infect 2011, 77:343-347. Antimicrobial Surveillance Network Study Group.
26. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious diseases society of America and American thoracic society infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
27. Stolz D., Christ-Crain M., Gencay M.M., Bingisser R., Huber P.R., Müller B., et al. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006, 136:434-440.
28. Wipf J.E., Lipsky B.A., Hirschmann J.V., Boyko E.J., Takasugi J., Peugeot R.L., et al. Diagnosing pneumonia by physical examination: relevant or relic?. Arch Intern Med 1999, 159:1082-1087.
29. Colon J.M., Grimeluis L., Thim L. Structural Characterization of a high molecular mass form of calcitonin and its corresponding N-terminal flanking peptide in a human medullary thyroid carcinoma. Biochem J 1988, 256:245-250.
30. Assicot M., Gendreil D., Carsin H., Raymond J., Guilbaud J., Bolmon C. High serum preocalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341:515-518.
31. Muller B., Becker K.I., Schachinger H., Rickenbacher P.R., Zimmerli W., Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care. Crit Care Med 2000, 8:977-983.
32. Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M.M., Huber P.R., Tamm M., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
33. Christ-Crain M., Stolz D., Bingisser R., Müller C., Miedinger D., Huber P.R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
34. Briel M., Schuetz P., Mueller B., Young J., Schild U., Nusbaumer C., et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008, 168:2000-2007.
35. Long W., Deng X., Zhang Y., Lu G., Xie J., Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011, 16:819-824.
36. Montassier E., Kenzi A., Porcheret A.S., Potel G., Batard E. Effect of early reassessment of antimicrobial prescription on antibiotic use in acute respiratory tract infections. Int J Infect Dis 2012, 16:73-74.
37. Agence française de sécurité sanitaire des produits de santé. Traitement antibiotique de la légionellose chez l'adulte-Mise au point. France, 2011.
38. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011, 17:1-59.
39. Kristoffersen K.B., Søgaard O.S., Wejse C., Black F.T., Greve T., Tarp B., et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission-a randomized trial. Clin Microbiol Infect 2009, 15:481-487.
40. Waterer G.W., Rello J., Wunderink R.G. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med 2011, 183:157-164.
41. Stijnis C., van Nieuwkoop C., van Dissel J.T. Procalcitonin-based guidelines and lower respiratory tract infections. JAMA 2010, 303:418-419.
42. El Moussaoui R., de Borgie C.A., van den Broek P., Hustinx W.N., Bresser P., van den Berk G.E., et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomised, double blind study. BMJ 2006, 332:1355.
43. Leophonte P., Choutet P., Gaillat J., Petitpretz P., Portier H., Montestruc F., et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect 2002, 32:369-381.
44. Dunbar L.M., Wunderink R.G., Habib M.P., Smith L.G., Tennenberg A.M., Khashab M.M., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003, 37:752-760.
45. Dunbar L.M., Khashab M.M., Kahn J.B., Zadeikis N., Xiang J.X., Tennenberg A.M. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004, 20:555-563.
46. Tellier G., Niederman M.S., Nusrat R., Patel M., Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004, 54:515-523.
47. Drehobl M.A., De Salvo M.C., Lewis D.E., Breen J.D. Single dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild to moderate community-acquired pneumonia in adults. Chest 2005, 128(4):2230-2237.
48. O'Doherty B., Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998, 17(12):828-833.
49. File T.M., Mandell L.A., Tillotson G., Kostov K., Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double blind study. J Antimicrob Chemother 2007, 60:112-120.
50. Dimopoulos G., Matthaiou D.K., Karageorgopoulos D.E., Grammatikos A.P., Athanassa Z., Falagas M.E. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008, 68:1841-1854.